![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GW Pasternak, SR Childers and SH Snyder
Administration of naloxazone, a hydrazone derivative of naloxone, to intact mice produces a prolonged inhibition of in vitro [3H]opiate binding lasting up to 3 days. The effect is selective since naloxazone treatment produces no changes in alpha or beta adrenergic, muscarinic or benzodiazepine receptor binding and the effects on opiate binding sites are not reproduced by non-narcotic hydrazines. Scatchard analyses of saturation experiments 24 hr after in vivo naloxazone treatment show an absence of high affinity binding sites of [3H]naloxone, [3H]dihydromorphine and 2-D-[3H]ala-met-enkephalinamide, although low affinity sites are relatively unaffected. Blockade of high affinity sites by naloxazone produces an 11-fold increase in the ED50 value for morphine analgesia at 24 hr with both tailflick and writhing assays. By contrast, naloxazone produces no change in the LD50 value for morphine. As high affinity binding returns to control levels over 3 days, ther ED50 for morphine analgesia in naloxazone-pretreated mice returns to control values. Accordingly, the analgetic, but not lethal, effects of morphine may be mediated by the high affinity subpopulation of opiate receptors.
This article has been cited by other articles:
|
|
 |
|
  L. Mahurter, C. Garceau, J. Marino, H. Schmidhammer, G. Toth, and G. W. Pasternak Separation of Binding Affinity and Intrinsic Activity of the Potent {micro}-Opioid 14-Methoxymetopon J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 247 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Bolan, R. J. Tallarida, and G. W. Pasternak Synergy between {micro} Opioid Ligands: Evidence for Functional Interactions among {micro} Opioid Receptor Subtypes J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 557 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-X. Pan, J. Xu, L. Mahurter, E. Bolan, M. Xu, and G. W. Pasternak Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene PNAS, November 20, 2001; 98(24): 14084 - 14089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Rossi, L. Leventhal, Y.-X. Pan, J. Cole, W. Su, R. J. Bodnar, and G. W. Pasternak Antisense Mapping of MOR-1 in Rats: Distinguishing between Morphine and Morphine-6beta -glucuronide Antinociception J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 109 - 114. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Ling, J. MacLeod, S Lee, S. Lockhart, and G. Pasternak Separation of morphine analgesia from physical dependence Science, October 26, 1984; 226(4673): 462 - 464. [Abstract] [PDF]
|
|
|
|
|
|
S. Snyder Drug and neurotransmitter receptors in the brain Science, April 6, 1984; 224(4644): 22 - 31. [Abstract] [PDF]
|
|
|
|
|
|
K Spiegel, I. Kourides, and G. Pasternak Prolactin and growth hormone release by morphine in the rat: different receptor mechanisms Science, August 20, 1982; 217(4561): 745 - 747. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
